concept

ACC

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ACC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

135Connections

30Hypotheses

0Analyses

50Outgoing

30Incoming

4Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ACC
Key Genes/Proteins	ABCA1, ACETYL-COA, ACLY, Albumin, AMPK, AND
Related Diseases	Als, ALS, Atherosclerosis, Autism, autism spectrum disorder

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    ACC["ACC"]
    ACC -->|"inhibits"| Als["Als"]
    ACC -->|"inhibits"| Ms["Ms"]
    ACC -->|"expressed in"| Atherosclerosis["Atherosclerosis"]
    ACC -->|"inhibits"| Tumor["Tumor"]
    ACC -->|"target for"| Fatty_Liver["Fatty Liver"]
    ACC -->|"inhibits"| ULK1["ULK1"]
    ACC -->|"activates"| AMPK["AMPK"]
    ACC -->|"inhibits"| Autophagy["Autophagy"]
    AMPK -->|"activates"| ACC
    KRAS["KRAS"] -->|"inhibits"| ACC
    ERK["ERK"] -->|"expressed in"| ACC
    CD36["CD36"] -->|"expressed in"| ACC
    FAS["FAS"] -->|"expressed in"| ACC
    SCD1["SCD1"] -->|"expressed in"| ACC
    SPR["SPR"] -->|"target for"| ACC
    LDL["LDL"] -->|"target for"| ACC

Outgoing (105)

Target	Relation	Type	Str
Polyunsaturated Fatty Acid Biosynthesis	regulates	pathway	0.85
Hepatic Lipogenesis	regulates	process	0.80
PV	regulates	gene	0.70
Tumor	inhibits	disease	0.65
Cancer	associated_with	disease	0.65
Lung Cancer	associated_with	disease	0.65
Tumor	therapeutic_target	disease	0.65
Carcinoma	associated_with	disease	0.65
Tumor	activates	disease	0.65
Cancer	inhibits	disease	0.65
Stroke	activates	disease	0.65
Neuroinflammation	activates	disease	0.65
ALS	activates	disease	0.65
Inflammation	activates	disease	0.65
Metabolic Syndrome	activates	disease	0.65
Ms	inhibits	disease	0.65
Ferroptosis	activates	disease	0.65
Als	therapeutic_target	disease	0.65
Autism	associated_with	disease	0.65
Als	inhibits	disease	0.65
Als	associated_with	disease	0.65
Atherosclerosis	expressed_in	disease	0.65
Fatty Liver	therapeutic_target	disease	0.65
AUTOPHAGY	inhibits	gene	0.60
Rb	regulates	protein	0.60
App	regulates	protein	0.60
AND	activates	gene	0.60
AND	inhibits	gene	0.60
AMPK	activates	gene	0.60
Autophagy	inhibits	pathway	0.60
ERK	expressed_in	gene	0.60
FAS	expressed_in	gene	0.60
CD36	expressed_in	gene	0.60
SPR	therapeutic_target	gene	0.60
SCD1	expressed_in	gene	0.60
Lipid Metabolism	therapeutic_target	pathway	0.60
ABCA1	expressed_in	gene	0.60
DHCR24	expressed_in	gene	0.60
LDLR	expressed_in	gene	0.60
SREBF2	expressed_in	gene	0.60
LPL	expressed_in	gene	0.60
HMGCR	expressed_in	gene	0.60
Lipid Metabolism	expressed_in	pathway	0.60
Cholesterol	expressed_in	pathway	0.60
MITOCHONDRIAL DYSFUNCTION	associated_with	gene	0.60
ACETYL-COA	therapeutic_target	gene	0.60
Oxidative Stress	activates	pathway	0.60
BDNF	activates	gene	0.60
PNN	expressed_in	gene	0.60
PV	expressed_in	gene	0.60

Incoming (30)

Source	Relation	Type	Str
AMPK	phosphorylates	protein	0.90
AMPK	activates	gene	0.64
ARNT2	inhibits	gene	0.60
SHANK3	interacts_with	gene	0.60
KCNH7	interacts_with	gene	0.60
NEURON	regulates	gene	0.60
DNA	associated_with	gene	0.60
metformin	targets	drug	0.60
KRAS	inhibits	gene	0.60
CANCER	associated_with	gene	0.60
ERK	expressed_in	gene	0.60
CD36	expressed_in	gene	0.60
FAS	expressed_in	gene	0.60
SCD1	expressed_in	gene	0.60
SPR	therapeutic_target	gene	0.60
LDL	therapeutic_target	gene	0.60
NEUROINFLAMMATION	activates	gene	0.60
INFLAMMATION	activates	gene	0.60
PTP1B	associated_with	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
JNK1	activates	gene	0.60
ATP	activates	gene	0.60
GAIN	activates	gene	0.60
JNK	activates	gene	0.60
CANCER	inhibits	gene	0.60
SST	regulates	gene	0.60
STROKE	activates	gene	0.60
ROS	inhibits	gene	0.60
DLK1	activates	gene	0.60
FERROPTOSIS	activates	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Chromatin Accessibility Restoration via BRD4 Modulation	0.768	neurodegeneration	Epigenetic reprogramming in aging neuron
APOE4 astrocytes exhibit impaired cholesterol efflux via ABC	0.758	neuroscience	APOE4-driven lipid metabolism dysregulat
APOE4-driven lysosome-to-ER cholesterol transport failure re	0.741	molecular-biology	Does APOE4's reduced lipid-binding direc
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
NRF2-Mediated Proteostatic Convergence: Shared Oxidative Str	0.700	neurodegeneration	-

Glucosylceramide Accumulation from GCase Deficiency Disrupts	0.700	neurodegeneration	-
APOE ε4 Drives Lipid Droplet Accumulation in a Unique Lipid-	0.697	alzheimer	APOE ε4 Lipid Metabolism Differences in
Loss of AQP4 Polarization Impairs Glymphatic Perivascular In	0.690	neurodegeneration	What are the specific molecular mechanis
hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-002	0.684	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
TREM2 R47H variant synergizes with APOE4 to collapse microgl	0.681	neuroscience	APOE4-driven lipid metabolism dysregulat
Bacterial Tyramine–Induced DOPAL Accumulation in Enteric Neu	0.680	neurodegeneration	What are the mechanisms by which gut mic
TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulati	0.670	neuroimmunology	What is the temporal sequence of TREM2 s
LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipida	0.668	lipidomics	Lipid metabolism dysregulation in Alzhei
mTORC1 displacement from lysosomal surface enables calcineur	0.650	neurodegeneration	What determines the specificity of calci
LRRK2 Haploinsufficiency Traps Microglia in Senescence-Like	0.650	parkinsons	-
TBK1 Insufficiency in Alzheimer Microglia Drives a Senescenc	0.633	alzheimers	-
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
PD genetic aging variants accelerating cell-type-specific ep	0.626	neurodegeneration	Genetic Aging Landscape Variants and Epi
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m	0.621	neurodegeneration	Mitochondrial transfer between astrocyte
Age-Accelerated miR-155 Upregulation Primes Nigral Microglia	0.610	neuroinflammation	How do regional, age, and sex-dependent
APOE4 Creates Accelerated, Compressed Reversibility Window	0.584	neurodegeneration	What is the optimal therapeutic window f
NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumul	0.566	developmental-neurobiology	Do perinatal immune challenges create pe
HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lys	0.560	neurodegeneration	What are the optimal oxygen pressure, du
TRIM21-Mediated Ubiquitination Creates Peripheral Epitope Gr	0.548	neurodegeneration	What determines the spatial organization
Glucosylceramide accumulation nucleates alpha-synuclein aggr	0.525	parkinsons	GBA-Synuclein Loop Therapeutics for PD
Neuronal Hypersensitivity to Feedback Inhibition by p62/Sequ	0.520	neurodegeneration	What mechanisms underlie neuronal resist
Hippocampal-Cortical Transcriptomic Divergence Reveals Accel	0.519	alzheimer	Allen Mouse Brain Aging Atlas: cross-age
Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Dow	0.517	neuroinflammation	What causes IBA1 low/negative microglia
TREM2-Mediated Microglial Metabolic Reprogramming Accelerate	0.494	neuroscience	Circuit-level neural dynamics in neurode
USP14 Inhibition to Accelerate Proteasomal Degradation of Sy	0.486	proteomics	Quantitative proteomics of the aging syn

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (4)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis	clinical	Alzheimer's Disease	0.400	0.50	human	completed	$6,550,000
Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti	validation	Neurodegeneration	0.400	0.50	human	completed	$3,000,000
Epigenetic Dysregulation Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000
Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disea	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Sertad4 Regulates Pathological Cardiac Remodeling. [PMID:41889836]	Francois A, Bermeo-Blanco O, Nguyen BT,	bioRxiv : the preprint server	2026
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of In [PMID:41874277]	Wang Z, Li P, Yin F, Zhang H, Wang S, Te	Journal of medicinal chemistry	2026
Cartilage targeting hydrogel nanoplatform degrades BRD4 to alleviate osteoarthri [PMID:41904167]	Zhao Q, Xu T, Du Z, Lu X, Zhang Y, Peng	Nature communications	2026
Molecular insights for the tumor suppressor role of SPOP in prostate cancer. [PMID:41707797]	Yan P, Xue X, Hou T, Wang J, Jiang W et	Biochim Biophys Acta Rev Cance	2026
Nutrient-driven histone acetylation underlies energy storage and mobilization. [PMID:41786244]	Chen L, Zhu L, Xiao H, Wang X, Xia F et	Mol Metab	2026
Alkyne Two-Phase Strategy: Rapid Generation of TK-285-Derived PROTACs as BRD4 De [PMID:41852276]	Yamakoshi H, Watanabe R, Segawa R, Ishih	Journal of medicinal chemistry	2026
The epigenetic and epitranscriptomic regulation of Brd4-Mettl3 axis on STING med [PMID:41917296]	Zhao J, Luo X, Wang Z, Luo W, Wu S, Ma X	Inflammation research : offici	2026
Punicalagin with anti-inflammatory activities affects Brd-4 mediated chromatin r [PMID:41807492]	Li H, Li Q, Wan T, Wang Y, Zhang S	Scientific reports	2026
Targeting BRD4-A Promising Therapeutic Option for Glioblastoma? [PMID:41828493]	Lindner M, Lisińska D, Kędzierzyńska A,	International journal of molec	2026
High-intensity interval training alleviates COPD-induced gastrocnemius muscle dy [PMID:41865095]	Zhu C, Peng W, Yang L, Zhang W	Journal of muscle research and	2026
A photothermal immune hydrogel dressing for enhanced post-melanoma resection tre [PMID:41877232]	Tan D, Zhu W, Liu S, Liao F, Xu X, Luo J	Journal of nanobiotechnology	2026
Recovery of FAM134A-mediated ER-phagy through BRD4 inhibition alleviates ethanol [PMID:40959274]	["Lim J", "Chae C", "Yoon J", "Cho J", "	International journal of biolo	2025
A human Tau expressing zebrafish model of progressive supranuclear palsy identif [PMID:39294122]	["Bai Q", "Shao E", "Ma D", "Jiao B", "S	Nature communications	2024
The expanding world of neuroscience. [PMID:39423798]	Unknown	Cell	2024
Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules. [PMID:38561350]	["Ma B", "Khan K", "Xu T", "Xeque Amada	Journal of the American Chemic	2024
Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing. [PMID:39315698]	["Altinbay M", "Wang J", "Chen J", "Sch\	Nucleic acids research	2024
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic [PMID:38643236]	["Rosenthal Z", "Fass D", "Payne N", "Sh	Scientific reports	2024
A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune [PMID:39002520]	["Song Z", "Li J", "He Y", "Wang X", "Ti	International immunopharmacolo	2024
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel dise [PMID:36710583]	["Ma Z", "Bolinger A", "Zhou J", "Tian B	Expert opinion on therapeutic	2023
Genetic and epigenetic regulators of retinal Müller glial cell reprogramming. [PMID:37846362]	["Xiao X", "Liao Z", "Zou J"]	Advances in ophthalmology prac	2023

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning ACC in their description or question text

APOE ε4 Drives Lipid Droplet Accumulation in a Unique Lipid-Associated Microglia

Score: 0.697 · alzheimer · 2026-04-27

APOE ε4 promotes excessive cholesterol esterification and neutral lipid droplet accumulation in a discrete lipid-associa

Loss of AQP4 Polarization Impairs Glymphatic Perivascular Influx, Causing Metabo

Score: 0.690 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The aquaporin-4 (AQP4) water channel represents a critical component of the brain

hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-0021 Accessibility for

Score: 0.684 · molecular-neurobiology · 2026-04-17

## **Molecular Mechanism and Rationale** The proposed therapeutic mechanism centers on the regulatory interplay between

TREM2 R47H variant synergizes with APOE4 to collapse microglial lipid clearance

Score: 0.681 · neuroscience · 2026-04-22

## **Molecular Mechanism and Rationale** The proposed mechanism centers on a catastrophic convergence of lipid homeosta

Bacterial Tyramine–Induced DOPAL Accumulation in Enteric Neurons

Score: 0.680 · neurodegeneration · 2026-04-22

## **Molecular Mechanism and Rationale** The proposed mechanism centers on a complex interplay between gut microbiota,

TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation

Score: 0.670 · neuroimmunology · 2026-04-15

## Mechanistic Overview TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation starts from the claim that modula

LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipidation and Reduce Micr

Score: 0.668 · lipidomics · 2026-04-25

LXRβ-selective agonism represents a targeted strategy to simultaneously enhance APOE lipidation and reduce microglial ch

mTORC1 displacement from lysosomal surface enables calcineurin access to TFEB

Score: 0.650 · neurodegeneration · 2026-04-21

## Mechanistic Overview mTORC1 displacement from lysosomal surface enables calcineurin access to TFEB starts from the cl

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro

PD genetic aging variants accelerating cell-type-specific epigenetic clock traje